冠心病抗炎治療的臨床研究進(jìn)展

打開文本圖片集

【摘要】炎癥是導(dǎo)致冠心病發(fā)生和發(fā)展的重要因素，抗炎治療成為進(jìn)一步降低冠心病殘余風(fēng)險的希望，然而目前臨床上并無規(guī)范的抗炎治療策略。近年來多項(xiàng)大規(guī)模的隨機(jī)、雙盲對照試驗(yàn)為尋找冠心病的抗炎治療策略指引了方向?，F(xiàn)結(jié)合近年來循證證據(jù)就冠心病抗炎治療的進(jìn)展做一綜述。

【關(guān)鍵詞】冠心?。豢寡字委?；殘余炎癥風(fēng)險

【DOI】10.16806/j.cnki.issn.1004-3934.2024.03.017

Clinical Research Progress in Anti-Inflammatory Therapy of Coronary Heart Disease

ZHUANG Wenwen，DU Mingliang，HUI Hui，ZHENG Xiaoqun

（Department of Coronary Heart Disease，Dalian Central Hospital，Dalian 116032，Liaoning，China）

【Abstract】Inflammation can lead to the development of coronary heart disease（CHD），and anti-inflammatory therapy has become the hope to further reduce the residual risk of CHD.However，there is no standard anti-inflammatory therapy strategy in clinical practice.In recent years，a number of large-scale randomized，double-blind，placebo-controlled clinical studies have guided the search for anti-inflammatory therapy for CHD.This article reviews the progress of anti-inflammatory therapy for CHD based on evidence-based research in recent years.

【Keywords】Coronary heart disease；Anti-inflammatory treatment；Residual inflammation risk

冠心病指冠狀動脈粥樣硬化引起管腔狹窄或閉塞，導(dǎo)致心肌缺血、缺氧或壞死，大量的循證證據(jù)已證實(shí)膽固醇濃度升高（主要由低密度脂蛋白顆粒轉(zhuǎn)運(yùn)）會促進(jìn)動脈粥樣硬化（atherosclerosis，AS）的發(fā)生和發(fā)展，降低膽固醇水平能延緩斑塊進(jìn)展，降低不良心血管事件的發(fā)生率，在冠心病的二級預(yù)防中起到基石作用［1］。（剩余13095字）